"BNP" for heart failure: Role of nesiritide in cardiovascular therapeutics

Congestive Heart Failure

Volumn 8, Issue 5, 2002, Pages 270-273

  Mills, Roger M ^a   Hobbs, Robert E ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; NESIRITIDE; NITROPRUSSIDE SODIUM;

ABDOMINAL PAIN; BOLUS INJECTION; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; PROTEIN STRUCTURE; REVIEW;

EID: 0036751185     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.01154.x     Document Type: Review

References (15)

1. Sudoh T, Kangawa K, Minammino H. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78-81.
2. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
3. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992;86:1081-1088.
4. Boland DG, Abraham WT. Natriuretic peptides in heart failure. Congest Heart Fail. 1998;4:23-33.
5. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-994.
6. Tsutamoto T, Wada A, Maeda, K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain nautriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
7. Grantham JA, Burnett JC. BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation. 1997;96:388-390.
8. Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;78:896-901.
9. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
10. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1996;94:3184-3189.
11. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
12. Mills RM, Le Jemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. J Am Coll Cardiol. 1999;34:155-162.
13. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated heart failure. N Engl J Med. 2000;343:246-253.
14. Publication Committee for the VMAC Investigators. Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure. JAMA. 2002;287:1531-1540.
15. Burger AJ, Johnson A, Horton DP. Effect of nesiritide versus dobutamine for treatment of acutely decompensated heart failure on cardiovascular adverse events [abstract]. J Card Fail. 1998;4(1):40. Abstract No. 150.